Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.

CPT: pharmacometrics & systems pharmacology - 1 Sept 2017

Thakkar Nilay, Guptill Jeffrey T, Aleš Kathy, Jacobus David, Jacobus Laura, Peloquin Charles, Cohen-Wolkowiez Michael, Gonzalez Daniel

Abstract excerpt

Lambert-Eaton myasthenia (LEM) is a rare autoimmune disorder associated with debilitating muscle weakness. There are limited treatment options and 3,4-diaminopyridine (3,4-DAP) free base is an investigational orphan drug used to treat LEM-related weakness. We performed a population pharmacokinetic/pharmacodynamic (PK/PD) analysis using 3,4-DAP and metabolite concentrations collected from a phase II study in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lower Extremity

Share to Models, Biological

Share to Muscle Weakness

Share to Potassium Channel Blockers

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28623849
DOI: 10.1002/psp4.12218
PMCID: PMC5613184

Genes

DAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.PMID 28623849Read ↗

Drug repurposing in skeletal muscle ion channelopathies.Semantic proximity Read ↗

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and TreatmentSemantic proximity Read ↗

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular DystrophySemantic proximity Read ↗

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.Semantic proximity Read ↗

Real-World Case Series of Efgartigimod for Generalized Myasthenia Gravis：Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom ControlSemantic proximity Read ↗

Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)Semantic proximity Read ↗

Efgartigimod efficacy and safety in refractory Myasthenia Gravis - UK’s first real-world experienceSemantic proximity Read ↗

Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.Semantic proximity Read ↗

Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Semantic proximity Read ↗

Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.Semantic proximity Read ↗

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell TherapySemantic proximity Read ↗

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.